Concert Pharmaceuticals, Inc. CNCE
Set alert
8.37 0.00 0.00%
At close · Mar 3
8.35 Day range 8.55
52-week range unavailable
- Open
- 8.38
- Prev close
- 8.37
- Mkt cap
- 0
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.35
- High
- 8.55
- Forward P/E
- 0.00
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 9, 2023
- 50-d avg
- 0.00
- 200-d avg
- 0.00
- 1y target
- 13.00
Analyst view
Consensus: buy
Buy
Price target (mean) 13.00 +55.3% upside
Now 8.37
- Target (low)
- 9.00
- Target (mean)
- 13.00
- Target (high)
- 17.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy1
- Buy4
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 5
- 2 months ago 5
- 3 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.63 | -0.81 – -0.52 | -1.01 | +37.6% | 110.00K | +746.2% | 4 |
| Next quarter | -0.87 | -0.87 – -0.87 | -1.03 | +15.5% | 0 | 0.0% | 1 |
| Current year | -2.76 | -3.00 – -2.63 | -2.33 | -18.5% | 120.00K | -99.6% | 4 |
| Next year | -2.69 | -4.07 – -1.22 | -2.76 | +2.5% | 13.57M | +11208.3% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 19, 2023 | JonesTrading | Downgrade | Buy | Hold |
| Sep 12, 2022 | Truist Securities | Maintained | — | Buy |
| Aug 24, 2022 | JonesTrading | Initiated | — | Buy |
| Oct 4, 2021 | Mizuho | Maintained | — | Buy |
| Feb 1, 2021 | Truist Securities | Maintained | — | Buy |
| Dec 15, 2020 | Berenberg | Initiated | — | Buy |
| Oct 2, 2019 | HC Wainwright & Co. | Reiterated | — | Buy |
| Sep 29, 2019 | SunTrust Robinson Humphrey | Maintained | — | Buy |
| Sep 29, 2019 | Mizuho | Maintained | — | Buy |
| Sep 3, 2019 | Mizuho | Maintained | — | Buy |
| Jun 23, 2019 | SunTrust Robinson Humphrey | Initiated | — | Buy |
| Jun 12, 2019 | Janney Montgomery Scott | Upgrade | Neutral | Buy |
| Apr 9, 2019 | UBS | Maintained | Buy | Buy |
| Apr 8, 2019 | Stifel | Maintained | Buy | Buy |
| Apr 8, 2019 | Mizuho | Maintained | Buy | Buy |
| Sep 12, 2018 | Janney Montgomery Scott | Initiated | — | Neutral |
| May 3, 2018 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 1, 2018 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jan 11, 2018 | Mizuho | Downgrade | Buy | Neutral |
| Oct 25, 2017 | Mizuho | Initiated | — | Buy |
| Jul 23, 2017 | HC Wainwright & Co. | Initiated | — | Buy |
| Jun 30, 2016 | Stifel | Initiated | — | Buy |
| Mar 8, 2016 | JMP Securities | Maintained | — | Market Outperform |
| Nov 8, 2015 | UBS | Downgrade | Buy | Neutral |
| Sep 22, 2015 | Brean Capital | Maintained | — | Buy |
| Aug 11, 2015 | Brean Capital | Initiated | — | Buy |
| Jun 25, 2014 | Ladenburg Thalmann | Initiated | — | Buy |
| Mar 18, 2014 | Roth Capital | Initiated | — | Buy |
| Mar 9, 2014 | UBS | Initiated | — | Buy |
| Mar 9, 2014 | UBS | Initiated | — | Buy |